Latest Profitability News

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Explorers led the Materials tape as fresh drill stories and new ground deals pulled buyers into small caps. Big miners still delivered, but the loudest moves came from companies offering investors a near-term catalyst.

Takeover chatter lit up Pepper Money, while Identitii ran hard after a regulator stepped in. At the other end, AMP slid despite higher profit, as investors weighed leadership change and legal costs.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Big moves came from disclosure drama, CEO change news, and one standout software upgrade. While several stocks jumped on results, a few gaps couldn’t hold as traders sold into early strength.

ECP Emerging Growth Limited reported a 6.9% portfolio loss for H1 2025, underperforming the ASX Small Ordinaries Index, yet declared a fully franked interim dividend and teased a significant special dividend.

WCM Global Growth Limited reported a net operating profit of $22.9 million for H1 FY2026 and announced an increased fully franked interim dividend, reinforcing its progressive dividend policy.

WCM Global Growth Limited reported a 51% drop in net profit for H1 FY2026 but announced an increased fully franked interim dividend, reflecting confidence in its investment strategy. The company’s portfolio outperformed its benchmark over 12 months despite a softer half-year return.

Katana Capital Limited has reported a remarkable 672% increase in half-year profit after tax to $5.8 million, driven by strong investment income and gains. The company maintains its quarterly dividend at 0.5 cents per share, reflecting confidence in its ongoing strategy.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.